BioGaia AB (LTS:0GTN) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0GTN BioGaia AB LTS:0GTN
94 GF Score
Price kr112.79
GF Value kr126.81
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioGaia AB Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0GTN
94GF Score
BioGaia AB LTS:0GTN
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioGaia AB (LTS:0GTN) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of kr112.79 is trading 11.1% below its estimated GF Value™ of kr126.81. GuruFocus considers BioGaia AB to be Modestly Undervalued.

Key valuation signals for LTS:0GTN:

  • Short Ratio:
  • GF Value™: kr126.81 vs. price of kr112.79 (11.1% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the LTS:0GTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioGaia AB Business Description

Other Exchanges BIOG B:SwedenBGLA:Germany
Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
94GF Score

Get the complete analysis for LTS:0GTN

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr112.79
Price
kr126.81
GF Value